Indian Domestic Formulations Market: A Roadmap to INR 5.5 Trillion by 2034

The Indian Domestic Formulations (DomForm) sector is poised to grow significantly, reaching an estimated INR 5.5 trillion market size by 2034, according to the latest report. With favorable demographic shifts, government policy reforms, and increasing healthcare access, the domestic pharmaceutical landscape is undergoing a transformative phase. This blog explores key trends, growth drivers, challenges, and future opportunities for the Indian pharmaceutical industry.

Key Growth Drivers in Domestic Formulations

Favorable Demographics and Rising Income Levels

• India’s population is forecasted to exceed 1.5 billion by 2034, with a substantial portion shifting to the middle-income category.
• Increasing life expectancy and higher incidence of non-communicable diseases (NCDs) such as cardiovascular and neurological conditions are driving demand for chronic care products.

Healthcare Insurance Penetration

• Health insurance coverage is expanding, expected to reach INR 2.2 lakh crore by 2028.
• Higher insurance penetration will make healthcare more accessible and reduce out-of-pocket expenses (OOPE) for households, boosting demand for branded pharmaceuticals.

Shifting Market Dynamics: The Rise of Branded Generics

The Indian pharmaceutical market is primarily dominated by Branded Generics (BGx), accounting for 90% of doctor prescriptions. BGx products leverage strong brand identity and doctor trust as a proxy for quality, especially given concerns around counterfeit drugs.

• Chronic Disease Care Expansion: Chronic therapies (e.g., cardiac and anti-diabetic drugs) have grown from 50% market share in FY15 to 53% in FY24 and are projected to dominate further.
• Brand-centric Strategy: The number of large pharmaceutical brands with annual sales exceeding INR 100 crore has increased 18x over the last decade, demonstrating the importance of brand-led growth.

Economic and Policy Tailwinds Supporting the Sector

The government’s Pharma Vision 2047 aims to ensure sustainable, equitable, and affordable healthcare. Several regulatory and financial reforms are set to improve market conditions:

• Trade Margin Rationalization (TMR) will limit channel margins, benefiting top pharma companies and improving access to affordable medicines.
• Jan Aushadhi Scheme aims to promote unbranded generics through 25,000 stores by 2026, enhancing access in underpenetrated regions.

Growth Opportunities Beyond Metro Areas

Despite its size, the Indian pharma market remains underpenetrated in rural and Tier 2+ regions. These areas offer vast growth potential as companies shift focus from urban centers. The report highlights:

• 65% of the population resides outside Tier 1 cities, creating a vast whitespace for pharma companies to expand.
• Trade Generics (TGx) are growing faster than the overall market at 14% CAGR, presenting new avenues for growth.

Impact of Manufacturing Variability and Compliance Standards

India has over 10,000 pharmaceutical manufacturing units, but the sector faces quality-related challenges:

• Only 2,000 facilities are WHO-GMP compliant, leading to trust issues.
• The government plans to increase compliance standards, potentially leading to consolidation and the closure of non-compliant units.

Projected Market Growth: INR 5.5 Trillion by 2034

The report projects the domestic formulations market to grow at 9-10% CAGR over the next decade, driven by:

• Expanding health insurance coverage and rising disposable income.
• Demand for chronic disease management due to lifestyle changes.
• Evolving business models with companies entering adjacent sectors like nutraceuticals, diagnostics, and medical devices.

Challenges and the Way Forward

• Regulatory Compliance: Stricter norms may lead to higher compliance costs, impacting smaller manufacturers.
• Brand Reliance: Heavy dependence on doctor-led marketing could pose challenges with changing regulations.
• Channel Expansion: Expanding into rural areas will require innovative marketing models and better infrastructure.

Conclusion

The Indian domestic formulations market offers immense opportunities for growth, backed by favorable demographics, policy support, and rising healthcare demand. Companies that can navigate regulatory changes, leverage brand power, and expand into underpenetrated regions will thrive in this evolving landscape. As the sector moves toward its INR 5.5 trillion target by 2034, innovation in business models, compliance upgrades, and market diversification will be critical to sustaining growth.

FAQs on Indian Domestic Formulations Market